Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Global hyperactivation of enhancers stabilizes human and mouse naïve pluripotency through inhibition of CDK8/19 Mediator kinases

  • Lynch, Cian J.
  • Bernad, Raquel
  • Martínez Val, Ana
  • Shahbazi, Marta N.
  • Nóbrega Pereira, Sandrina
  • Calvo Serrano, Isabel
  • Blanco Aparicio, Carmen
  • Tarantino, Carolina
  • Garreta, Elena
  • Richart Ginés, Laia
  • Alcazar, Noelia
  • Graña Castro, Osvaldo
  • Gómez López, Gonzalo
  • Aksoy, Irène
  • Muñoz-Martín, Maribel
  • Martinez, Sonia
  • Ortega, Sagrario
  • Prieto, Susana
  • Simboeck, Elisabeth
  • Camasses, Alain
  • Stephan-Otto Attolini, Camille
  • Fernandez, Agustín F.
  • Sierra, Marta I.
  • Fraga, Mario F.
  • Pastor, Joaquín
  • Fisher, Daniel
  • Montserrat, Núria
  • Savatier, Pierre
  • Muñoz, Javier
  • Zernicka-Goetz, Magdalena
  • Serrano Marugán, Manuel
Pluripotent stem cells (PSCs) transition between cell states in vitro and reflect developmental changes in the early embryo. PSCs can be stabilized in the naïve state by blocking extracellular differentiation stimuli, particularly FGF-MEK signaling. Here, we report that multiple features of the naïve state in human and mouse PSCs can be recapitulated without affecting FGF-MEK-signaling or global DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 kinases removes their ability to repress the Mediator complex at enhancers. Thus CDK8/19 inhibition increases Mediator-driven recruitment of RNA Pol II to promoters and enhancers. This efficiently stabilizes the naïve transcriptional program and confers resistance to enhancer perturbation by BRD4 inhibition. Moreover, naïve pluripotency during embryonic development coincides with a reduction in CDK8/19. We conclude that global hyperactivation of enhancers drives naïve pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 kinase activity. These principles may apply to other contexts of cellular plasticity.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 mediator kinases

  • Lynch, Cian J.
  • Bernad, Raquel
  • Martínez-Val, Ana
  • Shahbazi, Marta N.
  • Nóbrega-Pereira, Sandrina
  • Calvo, Isabel
  • Blanco-Aparicio, Carmen
  • Tarantino, Carolina
  • Garreta, Elena
  • Richart-Ginés, Laia
  • Alcazar, Noelia
  • Graña-Castro, Osvaldo
  • Gómez-López, Gonzalo
  • Aksoy, Irene
  • Muñoz-Martín, Maribel
  • Martinez, Sonia
  • Ortega, Sagrario
  • Prieto, Susana
  • Simboeck, Elisabeth
  • Camasses, Alain
  • Stephan-Otto Attolini, Camille
  • Fernández, Agustín F.
  • Sierra, Marta I.
  • Fraga, Mario F.
  • Pastor, Joaquín
  • Fisher, Daniel
  • Montserrat, Núria
  • Savatier, Pierre
  • Muñoz, Javier
  • Zernicka-Goetz, Magdalena
  • Serrano, Manuel
Pluripotent stem cells (PSCs) transition between cell states in vitro, reflecting developmental changes in the early embryo. PSCs can be stabilized in the naive state by blocking extracellular differentiation stimuli, particularly FGF–MEK signalling. Here, we report that multiple features of the naive state in human and mouse PSCs can be recapitulated without affecting FGF–MEK signalling or global DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 (hereafter CDK8/19) kinases removes their ability to repress the Mediator complex at enhancers. CDK8/19 inhibition therefore increases Mediator-driven recruitment of RNA polymerase II (RNA Pol II) to promoters and enhancers. This efficiently stabilizes the naive transcriptional program and confers resistance to enhancer perturbation by BRD4 inhibition. Moreover, naive pluripotency during embryonic development coincides with a reduction in CDK8/19. We conclude that global hyperactivation of enhancers drives naive pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 kinase activity. These principles may apply to other contexts of cellular plasticity., M.N.S. was funded by a Leverhulme Trust early career fellowship. Work in the laboratory of M.Z.-G. was funded by the Wellcome Trust (098287/Z/12/Z) and the European Research Council (ERC) (669198). I.C. was funded by the Secretaria d’Universitats i Recerca de la Generalitat de Catalunya and European Social Fund. I.A. and P.S. were supported by the Fondation pour la Recherche Medicale (DEQ20170336757), Infrastructure Nationale en Biologie et Santé INGESTEM (ANR-11-INBS-0009), IHU-B CESAME (ANR-10-IBHU-003), LabEx REVIVE (ANR-10-LABX-73), LabEx DEVweCAN (ANR-10-LABX-0061) and LabEx CORTEX (ANR-11-LABX-0042) of University of Lyon within the programme ‘Investissements d’Avenir’ (ANR-11-IDEX-0007). Research by J.P., S.M. and C.B.-A. was supported in part by a grant from the Spanish Ministry of Economy and Competitiveness (SAF2013-44267-R) and by the CNIO. Work in the laboratory of D.F. was funded by the Institut National du Cancer (PLBIO10-068 and PLBIO15-005) and the Ligue National Contre le Cancer (EL2018.LNCC/DF). Work in the laboratory of N.M. was funded by the ERC, under the European Union Horizon 2020 research and innovation programme (StG-2014–640525_REGMAMKID), the Spanish Association Against Cancer (AECC/LABAE16006), Carlos III Health Institute (Red TerCel, CardioCel, RD16/0011/0027), Ministry of Economy and Competitiveness (MINECO) projects SAF2017–89782-R, SAF2015–72617-EXP and RYC-2014–16242, and the CERCA/Government of Catalonia (2017 SGR 1306). Work in the laboratory of S.O. was funded by SAF2013–44866-R from MINECO Spain. Work in the laboratory of M.F.F. was funded by Plan Nacional de I+D+I 2013–2016/FEDER (PI15/00892, to M.F.F. and A.F.F.); the ISCIII-Subdireccion General de Evaluación y Fomento de la Investigación and Plan Nacional de I+D+I 2008–2011/FEDER (CP11/00131, to A.F.F.); IUOPA (to M.I.S.); and the Asturias Regional Government (GRUPIN14–052, to M.F.F.). The IUOPA is supported by the Obra Social Liberbank-Cajastur, Spain. Work in the laboratory of M.S. was funded by the CNIO, the IRB and by grants from Spanish Ministry of Economy co-funded by the European Regional Development Fund (SAF2017-82613-R), ERC (ERC-2014-AdG/669622), Botin Foundation, Banco Santander (Santander Universities Global Division), laCaixa Foundation and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Global hyperactivation of enhancers stabilizes human and mouse naïve pluripotency through inhibition of CDK8/19 Mediator kinases

  • Lynch, Cian J.
  • Bernad, Raquel
  • Martínez Val, Ana
  • Shahbazi, Marta N.
  • Nóbrega Pereira, Sandrina
  • Calvo Serrano, Isabel
  • Blanco Aparicio, Carmen
  • Tarantino, Carolina
  • Garreta, Elena
  • Richart Ginés, Laia
  • Alcazar, Noelia
  • Graña Castro, Osvaldo
  • Gómez López, Gonzalo
  • Aksoy, Irène
  • Muñoz-Martín, Maribel
  • Martinez, Sonia
  • Ortega, Sagrario
  • Prieto, Susana
  • Simboeck, Elisabeth
  • Camasses, Alain
  • Stephan-Otto Attolini, Camille
  • Fernandez, Agustín F.
  • Sierra, Marta I.
  • Fraga, Mario F.
  • Pastor, Joaquín
  • Fisher, Daniel
  • Montserrat, Núria
  • Savatier, Pierre
  • Muñoz, Javier
  • Zernicka-Goetz, Magdalena
  • Serrano Marugán, Manuel
Pluripotent stem cells (PSCs) transition between cell states in vitro and reflect developmental changes in the early embryo. PSCs can be stabilized in the naïve state by blocking extracellular differentiation stimuli, particularly FGF-MEK signaling. Here, we report that multiple features of the naïve state in human and mouse PSCs can be recapitulated without affecting FGF-MEK-signaling or global DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 kinases removes their ability to repress the Mediator complex at enhancers. Thus CDK8/19 inhibition increases Mediator-driven recruitment of RNA Pol II to promoters and enhancers. This efficiently stabilizes the naïve transcriptional program and confers resistance to enhancer perturbation by BRD4 inhibition. Moreover, naïve pluripotency during embryonic development coincides with a reduction in CDK8/19. We conclude that global hyperactivation of enhancers drives naïve pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 kinase activity. These principles may apply to other contexts of cellular plasticity.